Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis

Blood Cancer Journal

Volumn 5, Issue 10, 2015, Pages

  Guglielmelli, P ^a   Rotunno, G ^a   Fanelli, T ^a   Pacilli, A ^a   Brogi, G ^a   Calabresi, L ^a   Pancrazzi, A ^a   Vannucchi, A M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CALRETICULIN, HUMAN;

ADULT; AGED; FEMALE; GENE MUTATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; VALIDATION STUDY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; MYELOID METAPLASIA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CALRETICULIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; PROGNOSIS; YOUNG ADULT;

EID: 84989952230     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.90     Document Type: Letter

References (15)

1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med 2013; 369: 2379-2390.
2. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl J Med 2013; 369: 2391-2405.
3. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472-1477.
4. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I et al. Clinical effect of driver mutations of JAK2, CALR or MPL in primary myelofibrosis. Blood 2014; 124: 1062-1069.
5. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-1869.
6. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014; 28: 1494-1500.
7. Tefferi A, Lasho TL, Finke C, Belachew AA, Wassie EA, Ketterling RP et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia 2014; 28: 1568-1570.
8. Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL et al. Type 1 vs Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 2014; 28: 1568-1570.
9. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544-1551.
10. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014; 123: 1552-1555.
11. Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 2015; 29: 249-252.
12. Qiao C, Sun C, Ouyang Y, Wang JJ, Qian SX, Li JY et al. Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients. Haematologica 2014; 99: e182-e184.
13. Marty C, Harini N, Pecquet C, Chachoua I, Gryshkova V, Villeval J-L et al. Calr mutants retroviral mouse models lead to a myeloproliferative neoplasm mimicking an essential thrombocythemia progressing to a myelofibrosis. Blood 2014; 124: 157A.
14. Tefferi A, Lasho TL, Tischer A, Wassie EA, Finke CM, Belachew AA et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 2014; 124: 2465-2466.
15. Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617Fassociated myeloproliferative neoplasms: a joint European LeukemiaNet/ MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 2013; 27: 2032-2039.